inclusion criteria to be included in the trial the participant must: 1. be aged 18 and over 2. have clinical picture strongly suggestive of covid-19-related (with/without positive covid-19 test) and * risk count (as defined below) \>3 or * ≥ 3 if risk count includes "radiographic severity score \>3" 3. be considered an appropriate subject for intervention with immunomodulatory in the opinion of the supervising clinician 4. be able to be maintained on venous thromboembolism prophylaxis or current maintenance therapy during inpatient dosing period, according to local guidelines exclusion criteria the presence of any of the following will preclude participant inclusion: 1. inability to supply direct informed consent or assent from next of kin or independent healthcare provider on behalf of patient 2. mechanical ventilation at time of prior to dosing 3. contraindications to study drugs, including hypersensitivity to the active substances or any of the excipients 4. currently on any of the study investigational medicinal products 5. known unresolved neisseria meningitidis infection 6. unwilling to be vaccinated against neisseria meningitidis or receive prophylactic antibiotic cover until 2 weeks after vaccination 7. known active tuberculosis (no blood screening required) 8. known active hepatitis b or c (no blood screening required); active varicella zoster 9. concurrent participation in any interventional clinical trial including covid-19-related disease trials (observational studies allowed) 10. patient moribund at presentation or screening 11. pregnancy at screening (or unwillingness to adhere to pregnancy advice in protocol) 12. unwillingness to adhere to breastfeeding advice in protocol 13. either alanine transaminase or aspartate transaminase (alt or ast) \> 5 times the upper limit of normal 14. stage 4 severe chronic kidney disease or requiring dialysis (i.e. cockcroft gault estimated creatinine clearance \< 30 ml /min/1.73 m\^2) 15. currently receiving probenecid or chronic ivig treatment 16. any medical history or clinically relevant abnormality that is deemed by the principal investigator and/or medical monitor to make the patient ineligible for inclusion because of a safety concern. risk count patients will be given a risk count equal to the cumulative points received for the following criteria (no = 0 points, yes = 1 point): male gender, age \> 40 years, non-white ethnicity, diabetes, hypertension, neutrophils \> 8.0x10\^9/l, crp \> 40mg/l, radiographic severity score \>3

inclusion criteria to be included in the trial the participant must: 1. be aged 18 and over 2. have clinical picture strongly suggestive of covid-19-related (with/without positive covid-19 test) and * risk count (as defined below) \>3 or * ≥ 3 if risk count includes "radiographic severity score \>3" 3. be considered an appropriate subject for intervention with immunomodulatory in the opinion of the supervising clinician 4. be able to be maintained on venous thromboembolism prophylaxis or current maintenance therapy during inpatient dosing period, according to local guidelines exclusion criteria the presence of any of the following will preclude participant inclusion: 1. inability to supply direct informed consent or assent from next of kin or independent healthcare provider on behalf of patient 2. mechanical ventilation at time of prior to dosing 3. contraindications to study drugs, including hypersensitivity to the active substances or any of the excipients 4. currently on any of the study investigational medicinal products 5. known unresolved neisseria meningitidis infection 6. unwilling to be vaccinated against neisseria meningitidis or receive prophylactic antibiotic cover until 2 weeks after vaccination 7. known active tuberculosis (no blood screening required) 8. known active hepatitis b or c (no blood screening required); active varicella zoster 9. concurrent participation in any interventional clinical trial including covid-19-related disease trials (observational studies allowed) 10. patient moribund at presentation or screening 11. pregnancy at screening (or unwillingness to adhere to pregnancy advice in protocol) 12. unwillingness to adhere to breastfeeding advice in protocol 13. either alanine transaminase or aspartate transaminase (alt or ast) \> 5 times the upper limit of normal 14. stage 4 severe chronic kidney disease or requiring dialysis (i.e. cockcroft gault estimated creatinine clearance \< 30 ml /min/1.73 m\^2) 15. currently receiving probenecid or chronic ivig treatment 16. any medical history or clinically relevant abnormality that is deemed by the principal investigator and/or medical monitor to make the patient ineligible for inclusion because of a safety concern. risk count patients will be given a risk count equal to the cumulative points received for the following criteria (no = 0 points, yes = 1 point): male gender, age \> 40 years, non-white ethnicity, diabetes, hypertension, neutrophils \> 8.0x10\^9/l, crp \> 40mg/l, radiographic severity score \>3

inclusion criteria to be included in the trial the participant must: be aged 18 and over have clinical picture strongly suggestive of covid-19-related (with/without positive covid-19 test) and risk count (as defined below) >3 or ≥ 3 if risk count includes "radiographic severity score >3" be considered an appropriate subject for intervention with immunomodulatory in the opinion of the supervising clinician be able to be maintained on venous thromboembolism prophylaxis or current maintenance therapy during inpatient dosing period, according to local guidelines exclusion criteria the presence of any of the following will preclude participant inclusion: inability to supply direct informed consent or assent from next of kin or independent healthcare provider on behalf of patient mechanical ventilation at time of prior to dosing contraindications to study drugs, including hypersensitivity to the active substances or any of the excipients currently on any of the study investigational medicinal products known unresolved neisseria meningitidis infection unwilling to be vaccinated against neisseria meningitidis or receive prophylactic antibiotic cover until 2 weeks after vaccination known active tuberculosis (no blood screening required) known active hepatitis b or c (no blood screening required); active varicella zoster concurrent participation in any interventional clinical trial including covid-19-related disease trials (observational studies allowed) patient moribund at presentation or screening pregnancy at screening (or unwillingness to adhere to pregnancy advice in protocol) unwillingness to adhere to breastfeeding advice in protocol either alanine transaminase or aspartate transaminase (alt or ast) > 5 times the upper limit of normal stage 4 severe chronic kidney disease or requiring dialysis (i.e. cockcroft gault estimated creatinine clearance < 30 ml /min/1.73 m^2) currently receiving probenecid or chronic ivig treatment any medical history or clinically relevant abnormality that is deemed by the principal investigator and/or medical monitor to make the patient ineligible for inclusion because of a safety concern. risk count patients will be given a risk count equal to the cumulative points received for the following criteria (no = 0 points, yes = 1 point): male gender, age > 40 years, non-white ethnicity, diabetes, hypertension, neutrophils > 8.0x10^9/l, crp > 40mg/l, radiographic severity score >3

inclusion criteria to be included in the trial the participant must: be aged 18 and over have clinical picture strongly suggestive of covid-19-related (with/without positive covid-19 test) and risk count (as defined below) >3 or ≥ 3 if risk count includes "radiographic severity score >3" be considered an appropriate subject for intervention with immunomodulatory in the opinion of the supervising clinician be able to be maintained on venous thromboembolism prophylaxis or current maintenance therapy during inpatient dosing period, according to local guidelines exclusion criteria the presence of any of the following will preclude participant inclusion: inability to supply direct informed consent or assent from next of kin or independent healthcare provider on behalf of patient mechanical ventilation at time of prior to dosing contraindications to study drugs, including hypersensitivity to the active substances or any of the excipients currently on any of the study investigational medicinal products known unresolved neisseria meningitidis infection unwilling to be vaccinated against neisseria meningitidis or receive prophylactic antibiotic cover until 2 weeks after vaccination known active tuberculosis (no blood screening required) known active hepatitis b or c (no blood screening required); active varicella zoster concurrent participation in any interventional clinical trial including covid-19-related disease trials (observational studies allowed) patient moribund at presentation or screening pregnancy at screening (or unwillingness to adhere to pregnancy advice in protocol) unwillingness to adhere to breastfeeding advice in protocol either alanine transaminase or aspartate transaminase (alt or ast) > 5 times the upper limit of normal stage 4 severe chronic kidney disease or requiring dialysis (i.e. cockcroft gault estimated creatinine clearance < 30 ml /min/1.73 m^2) currently receiving probenecid or chronic ivig treatment any medical history or clinically relevant abnormality that is deemed by the principal investigator and/or medical monitor to make the patient ineligible for inclusion because of a safety concern. risk count patients will be given a risk count equal to the cumulative points received for the following criteria (no = 0 points, yes = 1 point): male gender, age > 40 years, non-white ethnicity, diabetes, hypertension, neutrophils > 8.0x10^9/l, crp > 40mg/l, radiographic severity score >3

inclusion criteria to be included in the trial the participant must: 1. be aged 18 and over 2. have clinical picture strongly suggestive of covid-19-related (with/without positive covid-19 test) and - risk count (as defined below) >3 or - ≥ 3 if risk count includes "radiographic severity score >3" 3. be considered an appropriate subject for intervention with immunomodulatory in the opinion of the supervising clinician 4. be able to be maintained on venous thromboembolism prophylaxis or current maintenance therapy during inpatient dosing period, according to local guidelines exclusion criteria the presence of any of the following will preclude participant inclusion: 1. inability to supply direct informed consent or assent from next of kin or independent healthcare provider on behalf of patient 2. mechanical ventilation at time of prior to dosing 3. contraindications to study drugs, including hypersensitivity to the active substances or any of the excipients 4. currently on any of the study investigational medicinal products 5. known unresolved neisseria meningitidis infection 6. unwilling to be vaccinated against neisseria meningitidis or receive prophylactic antibiotic cover until 2 weeks after vaccination 7. known active tuberculosis (no blood screening required) 8. known active hepatitis b or c (no blood screening required); active varicella zoster 9. concurrent participation in any interventional clinical trial including covid-19-related disease trials (observational studies allowed) 10. patient moribund at presentation or screening 11. pregnancy at screening (or unwillingness to adhere to pregnancy advice in protocol) 12. unwillingness to adhere to breastfeeding advice in protocol 13. either alanine transaminase or aspartate transaminase (alt or ast) > 5 times the upper limit of normal 14. stage 4 severe chronic kidney disease or requiring dialysis (i.e. cockcroft gault estimated creatinine clearance < 30 ml /min/1.73 m^2) 15. currently receiving probenecid or chronic ivig treatment 16. any medical history or clinically relevant abnormality that is deemed by the principal investigator and/or medical monitor to make the patient ineligible for inclusion because of a safety concern. risk count patients will be given a risk count equal to the cumulative points received for the following criteria (no = 0 points, yes = 1 point): male gender, age > 40 years, non-white ethnicity, diabetes, hypertension, neutrophils > 8.0x10^9/l, crp > 40mg/l, radiographic severity score >3

inclusion criteria to be included in the trial the participant must: 1. be aged 18 and over 2. have clinical picture strongly suggestive of covid-19-related (with/without positive covid-19 test) and - risk count (as defined below) >3 or - ≥ 3 if risk count includes "radiographic severity score >3" 3. be considered an appropriate subject for intervention with immunomodulatory in the opinion of the supervising clinician 4. be able to be maintained on venous thromboembolism prophylaxis or current maintenance therapy during inpatient dosing period, according to local guidelines exclusion criteria the presence of any of the following will preclude participant inclusion: 1. inability to supply direct informed consent or assent from next of kin or independent healthcare provider on behalf of patient 2. mechanical ventilation at time of prior to dosing 3. contraindications to study drugs, including hypersensitivity to the active substances or any of the excipients 4. currently on any of the study investigational medicinal products 5. known unresolved neisseria meningitidis infection 6. unwilling to be vaccinated against neisseria meningitidis or receive prophylactic antibiotic cover until 2 weeks after vaccination 7. known active tuberculosis (no blood screening required) 8. known active hepatitis b or c (no blood screening required); active varicella zoster 9. concurrent participation in any interventional clinical trial including covid-19-related disease trials (observational studies allowed) 10. patient moribund at presentation or screening 11. pregnancy at screening (or unwillingness to adhere to pregnancy advice in protocol) 12. unwillingness to adhere to breastfeeding advice in protocol 13. either alanine transaminase or aspartate transaminase (alt or ast) > 5 times the upper limit of normal 14. stage 4 severe chronic kidney disease or requiring dialysis (i.e. cockcroft gault estimated creatinine clearance < 30 ml /min/1.73 m^2) 15. currently receiving probenecid or chronic ivig treatment 16. any medical history or clinically relevant abnormality that is deemed by the principal investigator and/or medical monitor to make the patient ineligible for inclusion because of a safety concern. risk count patients will be given a risk count equal to the cumulative points received for the following criteria (no = 0 points, yes = 1 point): male gender, age > 40 years, non-white ethnicity, diabetes, hypertension, neutrophils > 8.0x10^9/l, crp > 40mg/l, radiographic severity score >3